Dans
The article discusses the controversy surrounding the approval of aducanumab, an experimental drug for Alzheimer’s disease, in Europe. The drug has been approved in the US, but the European Medicines Agency (EMA) has refused to approve it, citing inconsistent efficacy results in clinical trials. Despite strong support from patient organizations and some experts, the EMA ruled that the benefits of aducanumab do not outweigh its risks and costs. Therefore, the answer to your question is: the European Medicines Agency has refused to approve aducanumab for the treatment of Alzheimer’s disease.
Auteur/autrice
marco.pelerin@gmail.com